Intra-cellular therapies announces publication of lumateperone pivotal phase 3 study in bipolar depression in the american journal of psychiatry

In this study, lumateperone 42 mg showed significant reduction in depressive symptoms compared to placebo in patients with a major depressive episode associated with bipolar i or bipolar ii disorder and a favorable safety and tolerability profile. these anti-depressant effects were statistically significant in both bipolar i and bipolar ii disorder subgroup populations
ITCI Ratings Summary
ITCI Quant Ranking